Does Medicare cover GLP-1s for weight loss in 2027? The $50 Bridge copay and who qualifies
Weight-loss GLP-1s run through a temporary CMS program in 2027, not through your Part D plan. Here is who qualifies, what the $50 copay does and doesn't count toward, and what it means for your plan choice before December 7.
The short answer
Yes, for eligible people with Part D coverage. The Medicare GLP-1 Bridge covers Wegovy, Zepbound KwikPen, and Foundayo for weight management at a $50 monthly copay through December 31, 2027. You need a qualifying BMI, a prior authorization from your provider, and a lifestyle program. The planned BALANCE Model will not start in Medicare Part D in 2027.
- Copay: $50 for a one-month supply of Wegovy, Zepbound KwikPen, or Foundayo under the Medicare GLP-1 Bridge.
- Runs through: December 31, 2027. CMS extended it on April 21, 2026, after delaying the BALANCE Model in Part D.
- Doesn't count: the $50 does not count toward the $2,400 Part D cap or deductible, and Extra Help can't lower it.
- Who qualifies: Part D enrollees 18 or older with a BMI of 35 or higher, or a BMI of 27 to 34.9 plus a listed condition.
Applies to people with Medicare drug coverage (a stand-alone Part D plan, a Medicare Advantage plan with drug coverage, a Special Needs Plan, or an employer group waiver plan) who want a GLP-1 for weight management. If you have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease, your GLP-1 goes through your regular Part D plan instead.
Does Medicare cover GLP-1 drugs for weight loss in 2027?
Yes, for people who meet CMS’s criteria and have Medicare drug coverage. The coverage comes from the Medicare GLP-1 Bridge, a temporary CMS demonstration that started July 1, 2026 and now runs through December 31, 2027.
The law that created Part D still excludes drugs used for weight loss, so Part D plans can’t cover a GLP-1 for that purpose on their own. CMS uses its demonstration authority to pay for these drugs outside the Part D benefit. Your plan isn’t the one approving or paying the claim; a central CMS processor handles prior authorization and pharmacy payment.
The Bridge covers three drugs: Wegovy (injection or tablet), Zepbound (KwikPen only), and Foundayo tablets. Your cost is a $50 copay for a one-month supply, which is 28 or 30 days depending on the drug.
What happened to the BALANCE Model for Medicare?
It will not start in Medicare Part D in 2027. CMS had planned for the BALANCE Model to replace the Bridge on January 1, 2027, with Part D plans voluntarily opting in to cover GLP-1s for weight management at negotiated prices.
On April 21, 2026, the day after the plan application deadline, CMS announced it was delaying BALANCE in Part D pending more evaluation and data, and extending the Bridge through the end of 2027 instead. CMS has not given a new Part D start date. The Medicaid side of BALANCE is moving forward in states that choose to participate.
For you, the delay is mostly good news for 2027. Because the Bridge doesn’t depend on which plan you pick, you don’t need to find a “participating” plan during Open Enrollment to keep GLP-1 access next year.
Who qualifies for the $50 GLP-1 copay?
You must be 18 or older, have Medicare drug coverage, and meet one of three BMI tests when you start therapy. Eligible drug coverage includes a stand-alone Part D plan, a Medicare Advantage plan with drug coverage (HMO, HMO-POS, and local and regional PPO), a Special Needs Plan, an employer group waiver plan, and the LI NET program.
- BMI of 35 or higher, with no additional condition required.
- BMI of 30 or higher plus heart failure with preserved ejection fraction, uncontrolled high blood pressure, or chronic kidney disease stage 3a or higher.
- BMI of 27 or higher plus prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.
You are not eligible for the Bridge if your Part D plan already covers your GLP-1, or if you have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease. Those uses are Medicare-covered, so the drug goes through your regular Part D plan and its cost-sharing, which can be more or less than $50.
Your provider must send the prescription, complete the prior authorization when requested, and certify that you’re using the drug alongside a diet and exercise program. Medicare.gov has a short eligibility questionnaire on its weight loss drugs page.
How is the Bridge different from GLP-1 coverage through my Part D plan?
They are two separate payment routes with different rules. Which one applies depends on why the drug is prescribed, not which drug it is.
| 2027 | Medicare GLP-1 Bridge (weight management) | Your Part D plan (diabetes, sleep apnea, other covered uses) |
|---|---|---|
| Who pays | CMS, outside the Part D benefit | Your Part D or Medicare Advantage plan |
| Drugs | Wegovy, Zepbound KwikPen, Foundayo | Depends on the plan’s formulary |
| Your cost | $50 per month supply | Plan’s tier cost-sharing, deductible up to $700 |
| Counts toward $2,400 cap | No | Yes |
| Extra Help lowers it | No | Yes |
| Prescription Payment Plan | Not available | Available |
| Prior authorization | Central CMS processor, valid through December 31, 2027 unless you change drugs | Set by your plan |
One more 2027 change affects the second column. Ozempic, Rybelsus, and Wegovy have a Medicare-negotiated price starting January 1, 2027, which lowers what plans pay for covered uses. What you pay still depends on your plan’s tier and deductible.
What should I do during Open Enrollment if I take a GLP-1?
Choose your 2027 plan on your other medications and doctors. Bridge access is tied to having Medicare drug coverage, not to a specific plan, so the GLP-1 generally shouldn’t drive your plan choice for 2027. The exception is if your GLP-1 is prescribed for diabetes or sleep apnea, where the plan’s formulary matters a lot.
Open Enrollment runs October 15 to December 7, 2026, for coverage starting January 1, 2027. Medicare Advantage members can make one change from January 1 to March 31, 2027.
Checklist for GLP-1 users before December 7
- Confirm which route pays for your GLP-1 today: a Bridge approval letter from Medicare, or your Part D plan’s Explanation of Benefits.
- If you rely on the Bridge, keep some form of Medicare drug coverage for 2027. Dropping Part D ends Bridge eligibility and can add a permanent late enrollment penalty.
- If your plan covers your GLP-1 for diabetes or sleep apnea, check its 2027 tier, prior authorization, and quantity limits in the Annual Notice of Change.
- Compare plans on total annual cost for your other drugs, remembering the $50 Bridge copay won’t count toward the $2,400 cap.
- Before switching plans, call 1-800-MEDICARE to confirm your Bridge prior authorization carries over.
Will Medicare keep covering weight-loss GLP-1s in 2028?
No one can say yet. The Bridge is scheduled to end December 31, 2027, and CMS describes BALANCE in Part D as a potential future step, with no announced start date. A permanent change would require either a new CMS model or a change in the law.
We’ll update this post when CMS publishes 2028 guidance, most likely before the fall 2027 Open Enrollment Period. Our Part D page tracks the other drug-plan numbers for 2027.
Questions people ask
Does Medigap or Original Medicare alone give me access to the Bridge?
No. The Bridge requires Medicare drug coverage. Medigap policies don't include drug coverage, so you would need a stand-alone Part D plan alongside Original Medicare and Medigap.
Is Ozempic covered for weight loss under the Bridge?
No. The Bridge covers Wegovy (injection or tablet), Zepbound KwikPen, and Foundayo tablets. Ozempic is covered through Part D plans for type 2 diabetes, subject to each plan's formulary and prior authorization rules.
Do I have to renew my prior authorization in 2027?
Medicare.gov says an approved Bridge prior authorization stays valid, including refills and dose changes, through December 31, 2027. Switching to a different GLP-1 drug requires a new one.
I get Extra Help. Is my copay lower than $50?
No. Drugs filled under the Bridge are paid outside the Part D benefit, so Extra Help doesn't apply and the copay stays $50. You also can't spread it through the Medicare Prescription Payment Plan.
What happens after December 31, 2027?
CMS has not announced coverage for 2028. The Bridge is scheduled to end then, and CMS says BALANCE in Part D is delayed pending more data. Watch for CMS guidance before the 2028 Open Enrollment Period.
Can my doctor prescribe a Zepbound vial under the Bridge?
No. Only the Zepbound KwikPen is included. Single-dose Zepbound vials and single-dose pens are not covered under the Bridge.
Sources
- CMS, Medicare GLP-1 Bridge (overview and FAQs), July 13, 2026
- Medicare.gov, Weight loss drugs, accessed September 15, 2026
- CMS, Status Update on the Medicare GLP-1 Bridge Demo and BALANCE Model in Part D for CY 2027, April 21, 2026
- CMS, BALANCE Model, accessed September 15, 2026
- CMS, Negotiated Prices for Initial Price Applicability Year 2027 fact sheet, November 25, 2025
- KFF, What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge, May 11, 2026
Taking a GLP-1 and choosing a 2027 drug plan?
Send us your full medication list, including your GLP-1. A licensed advisor checks how every 2027 Part D and Medicare Advantage plan in your ZIP code handles your other drugs and replies within one business day. Free, no obligation.
Review my 2027 drug planCall or text (773) 657-9140Smart Insurance Agents LLC is an independent, licensed insurance agency and is not connected with or endorsed by the U.S. government or the federal Medicare program. We do not offer every plan available in your area. Please contact Medicare.gov, 1-800-MEDICARE, or your local State Health Insurance Assistance Program for information on all of your options. Content is for general information and is not a guarantee of coverage or rates; figures are subject to change by CMS and carriers.